Literature DB >> 35254509

Mechanisms of vascular damage in ANCA vasculitis.

David Massicotte-Azarniouch1, Carolina A Herrera1,2, J Charles Jennette2, Ronald J Falk1, Meghan E Free3.   

Abstract

The discovery of anti-neutrophil cytoplasmic antibodies (ANCA) and their antigenic targets, myeloperoxidase (MPO) and proteinase 3 (PR3), has led to further understanding as to the pathophysiologic processes that underlie vascular and tissue damage in ANCA vasculitis. ANCA trigger neutrophil activation leading to vascular damage in ANCA vasculitis. However, decades of study have determined that neutrophil activation alone is not sufficient to cause disease. Inflammatory stimuli are drivers of ANCA autoantigen expression and ANCA production. Certain infections or bacterial peptides may be crucial players in the initial steps of ANCA immunopathogenesis. Genetic and epigenetic alterations of gene encoding for MPO and PR3 provide additional disturbances to the immune homeostasis which provide a substrate for pathogenic ANCA formation from an adaptive immune system predisposed to autoreactivity. Promoted by inflammatory cytokines, ANCA binding leads to neutrophil activation, a process characterized by conformational changes, production and release of cytotoxic substances, and alternative complement pathway activation, thus creating an intense inflammatory milieu. This cascade of events perpetuates a vicious cycle of further inflammatory cell recruitment and activation, culminating in tissue necrosis. Our understanding of the pathogenic process in ANCA vasculitis paves the way for the development of therapies targeting crucial steps in this process. The greater appreciation of the role for complement, monocytes, and the adaptive immune system has already led to novel complement blockers and is poised to lead to further innovations which will allow for tailored antigen- or cell-specific immunotherapy targeting the autoimmune process without exposure to undue risks or toxicities.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  ANCA vasculitis; Autoantibody; B cell; Glomerulonephritis; Neutrophil; T cell

Mesh:

Substances:

Year:  2022        PMID: 35254509      PMCID: PMC9064952          DOI: 10.1007/s00281-022-00920-0

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   11.759


  156 in total

1.  Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis.

Authors:  Maria Pia Rastaldi; Franco Ferrario; Andor Crippa; Giacomo Dell'antonio; Donatella Casartelli; Carlo Grillo; Giuseppe D'Amico
Journal:  J Am Soc Nephrol       Date:  2000-11       Impact factor: 10.121

2.  De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells.

Authors:  Z Zhou; C Richard; H A Ménard
Journal:  J Rheumatol       Date:  2000-10       Impact factor: 4.666

3.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.

Authors:  Roberto Lande; Josh Gregorio; Valeria Facchinetti; Bithi Chatterjee; Yi-Hong Wang; Bernhard Homey; Wei Cao; Yui-Hsi Wang; Bing Su; Frank O Nestle; Tomasz Zal; Ira Mellman; Jens-Michael Schröder; Yong-Jun Liu; Michel Gilliet
Journal:  Nature       Date:  2007-09-16       Impact factor: 49.962

4.  Antibodies against granule proteins activate neutrophils in vitro.

Authors:  L A Charles; M L Caldas; R J Falk; R S Terrell; J C Jennette
Journal:  J Leukoc Biol       Date:  1991-12       Impact factor: 4.962

5.  Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool.

Authors:  L Halbwachs-Mecarelli; G Bessou; P Lesavre; S Lopez; V Witko-Sarsat
Journal:  FEBS Lett       Date:  1995-10-23       Impact factor: 4.124

6.  Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers.

Authors:  U Erdbrügger; T Hellmark; D O Bunch; D A Alcorta; J C Jennette; R J Falk; P H Nachman
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

7.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

8.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

Review 9.  Multiple Phenotypic Changes Define Neutrophil Priming.

Authors:  Irina Miralda; Silvia M Uriarte; Kenneth R McLeish
Journal:  Front Cell Infect Microbiol       Date:  2017-05-29       Impact factor: 5.293

10.  Complement Factor H Inhibits Anti-Neutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation by Interacting With Neutrophils.

Authors:  Su-Fang Chen; Feng-Mei Wang; Zhi-Ying Li; Feng Yu; Min Chen; Ming-Hui Zhao
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

View more
  2 in total

1.  Diseases of blood vessels: Immune system involvement in vasculitis and vasculopathy.

Authors:  Peter C Grayson; Mariana J Kaplan
Journal:  Semin Immunopathol       Date:  2022-05       Impact factor: 9.623

Review 2.  Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management.

Authors:  Shangqing Ge; Xingyu Zhu; Qinyao Xu; Junyan Wang; Cheng An; Ying Hu; Fan Yang; Xinyi Wang; Yipin Yang; Shuwen Chen; Ruimin Jin; Haiyan Li; Xinchen Peng; Yue Liu; Junnan Xu; Minhui Zhu; Zongwen Shuai
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.